Mediwound Ltd (NASDAQ:MDWD) – Equities research analysts at SunTrust Banks lifted their Q1 2019 earnings estimates for Mediwound in a report issued on Tuesday, March 26th, Zacks Investment Research reports. SunTrust Banks analyst B. Nudell now anticipates that the biopharmaceutical company will post earnings of ($0.12) per share for the quarter, up from their previous estimate of ($0.19). SunTrust Banks also issued estimates for Mediwound’s Q3 2019 earnings at ($0.19) EPS, FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($0.41) EPS and FY2021 earnings at ($0.35) EPS.
Mediwound (NASDAQ:MDWD) last announced its earnings results on Monday, March 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.09. Mediwound had a negative return on equity of 398.49% and a negative net margin of 31.08%. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $0.80 million.
MDWD stock traded up $0.39 during trading on Friday, hitting $4.84. The company had a trading volume of 88,797 shares, compared to its average volume of 95,817. Mediwound has a 12 month low of $3.76 and a 12 month high of $7.35. The stock has a market capitalization of $131.55 million, a PE ratio of -9.88 and a beta of 0.69.
Several institutional investors have recently modified their holdings of the business. Deutsche Bank AG raised its position in shares of Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 16,840 shares during the last quarter. Millennium Management LLC increased its position in shares of Mediwound by 33.2% in the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 17,048 shares in the last quarter. Sargent Investment Group LLC bought a new stake in shares of Mediwound in the 4th quarter valued at $55,000. ETF Managers Group LLC increased its position in shares of Mediwound by 57.4% in the 4th quarter. ETF Managers Group LLC now owns 48,085 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 17,531 shares in the last quarter. Finally, Worth Venture Partners LLC bought a new stake in shares of Mediwound in the 3rd quarter valued at $306,000. Institutional investors own 29.86% of the company’s stock.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Article: Put Option Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.